Pfizer discontinues Trubion's TRU-015 for rheumatoid arthritis

Pfizer has discontinued development of Trubion Pharmaceuticals' TRU-015, which was in Phase II development for the treatment of rheumatoid arthritis under the companies' CD20 collaboration. However, it intends to continue development of a follow-on compound, SBI-087.